NAD+ (nicotinamide adenine dinucleotide) is a cellular coenzyme in all living cells. It is essential for numerous biological processes, cellular energy, and mitochondrial health. Recent and rapidly expanding scientific research indicates that increasing NAD+ represents a promising therapeutic strategy for age-associated degenerative diseases and improving healthspan. NMN – (Nicotinamide mononucleotide) is a direct precursor to NAD+ and has been proven to raise plasma concentrations of NAD+ in human studies. Recommended dosages of NMN range from 250mg – 1000mg per day, where NMN activity may be limited through oral absorption and degradation. Natroceutics NMN utilizes an advanced liposomal delivery technology to improve the bioavailability, stability, and efficacy of NMN for all users. A human pilot study demonstrated that the participant’s cellular concentration of NAD+ doubled in 15 days when using the equivalent of 4 capsules of Natroceutics NMN per day.